John W. Brown

John W. Brown did not found Stryker, did not invent its products, and did not even want the job the first time it was offered to him ^[5][6]. He was a 42-year-old chemical engineer running a surgical-instrument subsidiary for Squibb when the small, leaderless Kalamazoo company came calling in 1976, in the chaos after its president Lee Stryker, son of the founder, the orthopedic surgeon Homer Stryker, died in a Wyoming plane crash ^[1][6]. Brown said no. The board came back in 1977, and this time, apprehensively, he said yes ^[5][6]. What he did over the next twenty-seven years was rarer than invention: he imposed a single, relentless discipline on a company and refused, year after year, to let it slip.

The discipline had a name and a number. Brown had studied the emerging growth companies of his era and concluded that the great ones never let their growth rate fall below a floor; so in 1979, taking Stryker public, he stood before the firm and declared that net earnings would grow at least 20 percent every single year ^[4][6]. He did not call it a target or an aspiration. He called it "the law" ^[4][6]. For more than two decades the company delivered, Stryker hit its 20-percent mark for roughly twenty straight years, a streak so improbable that it became a case study in the management literature ^[2][4].

The early moves were unglamorous and decisive. Brown found a sales force gutted by a switch to salary and put it back on commission; he wrote the company's first real budget, cut operating fat, and made every manager set and own a number ^[1][6]. Then he widened the franchise. In 1979 he bought the three-year-old hip-implant maker Osteonics, planting Stryker in the vast orthopedic-reconstruction market it would come to dominate ^[1]. By the mid-1980s he had broken the firm into autonomous operating divisions, each with its own profit-and-loss statement and its own piece of "the law" to carry ^[1][2].

The enforcement was theatrical. At the annual division reviews, the executives whose units had made their 20-percent march were invited to the chairman's breakfast table; those who had missed ate elsewhere, well fed, but conspicuously exiled ^[2]. Divisions that fell short were handed the company's mock "Snorkel Award," a reminder that they were in over their heads ^[2]. Brown did not accept the usual alibis. Bad market, unfavorable currency, soft economy, none of it counted ^[2][7]. The point of the law, he understood, was that it had to bind in good years too: in booms he refused to over-stretch, in downturns he refused to coast ^[2].

The defining gamble came in 1998. Brown agreed to pay Pfizer roughly $1.9 billion for Howmedica, its orthopedic division, in a deal repriced to $1.65 billion in cash by year's end as markets wobbled ^[3][8]. It was a company nearly Stryker's own size, and digesting it broke the sacred 20-percent earnings streak for the first time in twenty-one years ^[1][3]. But it vaulted Stryker to the front rank of the world orthopedic-implant business, with something like 15 percent of a $10-billion global market, and the growth machine soon resumed ^[1][3].

By the time Brown stepped down as CEO at the end of 2004, staying on as chairman until 2009, Stryker's revenue had risen from roughly $23 million the year he arrived to about $4 billion, its workforce from 325 to some 15,000 ^[6][7]. A dollar invested in the stock at the 1979 IPO and held into the new century multiplied hundreds of times over ^[2]. He had not changed medicine the way Homer Stryker's turning frame and cast cutter had; he had done something a founder rarely can, he had turned a single inventor's workshop into a durable, compounding institution ^[1][2].

John Wilford Brown was born September 15, 1934, in Paris, Tennessee, into a farm family marked by the Depression ^[6]. His father had worked for a General Motors subsidiary and lost the job in 1929, and the hard years left their stamp; Brown would later say the early experience of "getting by" gave him a lifelong conviction about preserving assets ^[7]. As a boy he worked the fields, plowing first behind a mule and later with a tractor, an upbringing that bred the plain, unsentimental discipline he carried into the boardroom ^[5][7].

He took a roundabout path to industry. After graduating high school in 1953 and attending Freed-Hardeman College, he earned a chemical-engineering degree from Auburn University in 1957, where he met his future wife, Rosemary Kopel, a chemistry graduate of the same class ^[5][6]. His first jobs had nothing to do with medicine: he engineered at Ormet, an aluminum venture, and then worked on rocket propellants at Thiokol ^[5]. The pivot came when he joined Squibb, rising to become assistant to the president and then head of Edward Weck & Company, a surgical-instrument subsidiary, where he doubled sales and tripled profits in five years ^[5][6].

That record is what brought Kalamazoo to his door. Stryker, founded in 1941 by Dr. Homer Stryker as the Orthopedic Frame Company, maker of the Wedge turning frame, the cast cutter, and the Circ-O-Lectric bed, was rudderless after Lee Stryker's death and badly needed an operator ^[1][6]. Brown turned the board down in 1976, then accepted in 1977. He was forty-two, an outsider to orthopedics, and stepping into a company that revered its founder's name ^[5][6].

John Brown's monument is not a device but a discipline. The "20-Mile March" he ran at Stryker, a self-imposed minimum hit year after year, in good weather and bad, became one of the most cited cases in modern management writing after Jim Collins built a chapter of Great by Choice around it, holding Stryker up as the kind of company that thrives precisely because it refuses to be swept along by booms and busts ^[2]. Few executives have ever translated a personal temperament, the asset-preserving caution of a Depression farm boy, so cleanly into a corporate operating system ^[2][7].

The numbers are the rest of the argument. Brown took a roughly $23-million company with 325 employees and left, twenty-seven years later, a roughly $4-billion enterprise of some 15,000, having compounded shareholder value hundreds of times over and made Stryker a global leader in orthopedic implants ^[1][2][6]. The Howmedica deal that briefly broke his streak in 1998 turned out to be the platform for the company's next era of scale ^[1][3]. Homer Stryker's name still sits on the door, and on the Western Michigan University medical school it now graces, but it was the outsider engineer from Tennessee who proved a founder's workshop could be turned into a compounding machine, and who wrote the playbook for doing it without ever telling a lie, stealing, or cheating to make the number ^[1][5].